vs

Side-by-side financial comparison of MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) and PLAYSTUDIOS, Inc. (MYPS). Click either name above to swap in a different company.

PLAYSTUDIOS, Inc. is the larger business by last-quarter revenue ($55.4M vs $49.9M, roughly 1.1× MARAVAI LIFESCIENCES HOLDINGS, INC.). PLAYSTUDIOS, Inc. runs the higher net margin — -24.7% vs -71.6%, a 46.8% gap on every dollar of revenue. On growth, MARAVAI LIFESCIENCES HOLDINGS, INC. posted the faster year-over-year revenue change (-11.8% vs -18.3%). PLAYSTUDIOS, Inc. produced more free cash flow last quarter ($3.6M vs $-24.9M). Over the past eight quarters, MARAVAI LIFESCIENCES HOLDINGS, INC.'s revenue compounded faster (-11.9% CAGR vs -15.6%).

Maravai LifeSciences Holdings is a global life sciences firm developing critical reagents, diagnostic products, and tech solutions to support biopharma research, drug development, clinical diagnostics, and cell/gene therapy manufacturing. It serves biotech, pharma, research bodies and labs worldwide across three core segments.

PLAYSTUDIOS, Inc. develops and publishes free-to-play social and casual casino games for mobile, desktop and social platforms. It operates a loyalty rewards program that lets players redeem in-game achievements for real-world benefits including travel, dining and event tickets, serving markets across North America, Europe and Asia Pacific.

MRVI vs MYPS — Head-to-Head

Bigger by revenue
MYPS
MYPS
1.1× larger
MYPS
$55.4M
$49.9M
MRVI
Growing faster (revenue YoY)
MRVI
MRVI
+6.4% gap
MRVI
-11.8%
-18.3%
MYPS
Higher net margin
MYPS
MYPS
46.8% more per $
MYPS
-24.7%
-71.6%
MRVI
More free cash flow
MYPS
MYPS
$28.5M more FCF
MYPS
$3.6M
$-24.9M
MRVI
Faster 2-yr revenue CAGR
MRVI
MRVI
Annualised
MRVI
-11.9%
-15.6%
MYPS

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
MRVI
MRVI
MYPS
MYPS
Revenue
$49.9M
$55.4M
Net Profit
$-35.7M
$-13.7M
Gross Margin
25.8%
Operating Margin
-117.9%
-17.7%
Net Margin
-71.6%
-24.7%
Revenue YoY
-11.8%
-18.3%
Net Profit YoY
-37.7%
38.9%
EPS (diluted)
$-0.24
$-0.12

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MRVI
MRVI
MYPS
MYPS
Q4 25
$49.9M
$55.4M
Q3 25
$41.6M
$57.6M
Q2 25
$47.4M
$59.3M
Q1 25
$46.9M
$62.7M
Q4 24
$56.6M
$67.8M
Q3 24
$69.0M
$71.2M
Q2 24
$69.4M
$72.6M
Q1 24
$64.2M
$77.8M
Net Profit
MRVI
MRVI
MYPS
MYPS
Q4 25
$-35.7M
$-13.7M
Q3 25
$-25.6M
$-9.1M
Q2 25
$-39.6M
$-2.9M
Q1 25
$-29.9M
$-2.9M
Q4 24
$-25.9M
$-22.4M
Q3 24
$-97.1M
$-3.1M
Q2 24
$-9.8M
$-2.6M
Q1 24
$-12.1M
$-567.0K
Gross Margin
MRVI
MRVI
MYPS
MYPS
Q4 25
25.8%
Q3 25
13.6%
Q2 25
16.4%
Q1 25
16.5%
Q4 24
34.3%
Q3 24
46.7%
Q2 24
44.4%
Q1 24
40.3%
Operating Margin
MRVI
MRVI
MYPS
MYPS
Q4 25
-117.9%
-17.7%
Q3 25
-98.6%
-13.6%
Q2 25
-139.8%
-5.9%
Q1 25
-104.9%
-4.4%
Q4 24
-66.7%
-33.1%
Q3 24
-239.9%
-6.7%
Q2 24
-19.4%
-5.5%
Q1 24
-29.4%
-2.2%
Net Margin
MRVI
MRVI
MYPS
MYPS
Q4 25
-71.6%
-24.7%
Q3 25
-61.4%
-15.8%
Q2 25
-83.5%
-5.0%
Q1 25
-63.9%
-4.6%
Q4 24
-45.8%
-33.1%
Q3 24
-140.6%
-4.3%
Q2 24
-14.1%
-3.6%
Q1 24
-18.8%
-0.7%
EPS (diluted)
MRVI
MRVI
MYPS
MYPS
Q4 25
$-0.24
$-0.12
Q3 25
$-0.18
$-0.07
Q2 25
$-0.27
$-0.02
Q1 25
$-0.21
$-0.02
Q4 24
$-0.21
$-0.18
Q3 24
$-0.68
$-0.02
Q2 24
$-0.07
$-0.02
Q1 24
$-0.09
$0.00

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MRVI
MRVI
MYPS
MYPS
Cash + ST InvestmentsLiquidity on hand
$216.9M
$104.9M
Total DebtLower is stronger
$291.8M
Stockholders' EquityBook value
$212.4M
$227.9M
Total Assets
$770.6M
$290.6M
Debt / EquityLower = less leverage
1.37×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MRVI
MRVI
MYPS
MYPS
Q4 25
$216.9M
$104.9M
Q3 25
$243.6M
$106.3M
Q2 25
$269.9M
$112.9M
Q1 25
$285.1M
$107.1M
Q4 24
$322.4M
$109.2M
Q3 24
$578.2M
$105.2M
Q2 24
$573.2M
$106.3M
Q1 24
$561.7M
$127.0M
Total Debt
MRVI
MRVI
MYPS
MYPS
Q4 25
$291.8M
Q3 25
$292.8M
Q2 25
$293.9M
Q1 25
$294.9M
Q4 24
$295.9M
Q3 24
$521.7M
Q2 24
$522.5M
Q1 24
$523.3M
Stockholders' Equity
MRVI
MRVI
MYPS
MYPS
Q4 25
$212.4M
$227.9M
Q3 25
$245.4M
$238.9M
Q2 25
$265.9M
$245.3M
Q1 25
$300.6M
$244.1M
Q4 24
$325.3M
$244.7M
Q3 24
$344.9M
$265.2M
Q2 24
$434.7M
$263.6M
Q1 24
$410.7M
$288.4M
Total Assets
MRVI
MRVI
MYPS
MYPS
Q4 25
$770.6M
$290.6M
Q3 25
$849.2M
$299.2M
Q2 25
$897.0M
$316.2M
Q1 25
$959.8M
$313.8M
Q4 24
$1.0B
$323.0M
Q3 24
$1.3B
$330.6M
Q2 24
$1.4B
$333.4M
Q1 24
$1.4B
$357.5M
Debt / Equity
MRVI
MRVI
MYPS
MYPS
Q4 25
1.37×
Q3 25
1.19×
Q2 25
1.11×
Q1 25
0.98×
Q4 24
0.91×
Q3 24
1.51×
Q2 24
1.20×
Q1 24
1.27×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MRVI
MRVI
MYPS
MYPS
Operating Cash FlowLast quarter
$-22.8M
$3.7M
Free Cash FlowOCF − Capex
$-24.9M
$3.6M
FCF MarginFCF / Revenue
-49.9%
6.5%
Capex IntensityCapex / Revenue
4.2%
0.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-70.7M
$25.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MRVI
MRVI
MYPS
MYPS
Q4 25
$-22.8M
$3.7M
Q3 25
$-15.2M
$5.7M
Q2 25
$-10.3M
$13.6M
Q1 25
$-9.4M
$3.3M
Q4 24
$-14.6M
$11.6M
Q3 24
$13.1M
$14.6M
Q2 24
$17.4M
$14.5M
Q1 24
$-8.5M
$5.0M
Free Cash Flow
MRVI
MRVI
MYPS
MYPS
Q4 25
$-24.9M
$3.6M
Q3 25
$-18.1M
$5.4M
Q2 25
$-13.1M
$13.2M
Q1 25
$-14.6M
$3.2M
Q4 24
$-20.5M
$11.5M
Q3 24
$4.5M
$13.9M
Q2 24
$7.9M
$12.8M
Q1 24
$-14.1M
$3.6M
FCF Margin
MRVI
MRVI
MYPS
MYPS
Q4 25
-49.9%
6.5%
Q3 25
-43.4%
9.3%
Q2 25
-27.7%
22.3%
Q1 25
-31.2%
5.1%
Q4 24
-36.2%
16.9%
Q3 24
6.6%
19.6%
Q2 24
11.4%
17.6%
Q1 24
-22.0%
4.6%
Capex Intensity
MRVI
MRVI
MYPS
MYPS
Q4 25
4.2%
0.2%
Q3 25
7.0%
0.5%
Q2 25
6.1%
0.7%
Q1 25
11.2%
0.2%
Q4 24
10.3%
0.2%
Q3 24
12.4%
0.9%
Q2 24
13.8%
2.4%
Q1 24
8.8%
1.9%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

MRVI
MRVI

Cygnus Segment$27.2M54%
Other$18.4M37%
Shipping And Handling$4.3M9%

MYPS
MYPS

Segment breakdown not available.

Related Comparisons